Want to see PRPH full AI Analyst Report?
PRPH Stock Chart & Stats
$0.18
-$0.13(-18.06%)
At close: 4:00 PM EST
$0.18
-$0.13(-18.06%)
Day’s Range― - ―
52-Week Range$0.07 - $6.66
Previous CloseN/A
Volume469.10K
Average Volume (3M)100.67K
Market Cap
$722.44K
Enterprise Value$8.88M
Total Cash (Recent Filing)$31.00K
Total Debt (Recent Filing)$8.91M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding9,493,287
10 Day Avg. Volume168,110
30 Day Avg. Volume100,672
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.88
P/FCF Ratio-0.46
Enterprise Value/Market Cap12.30
Enterprise Value/Revenue2.62
Enterprise Value/Gross Profit8.67
Enterprise Value/Ebitda-0.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Streams (OTC Products + Diagnostics)A dual business model spanning OTC consumer health and clinical diagnostics provides durable revenue optionality. Consumer retail channels and lab testing have different demand drivers and payor dynamics, helping reduce reliance on one market and offering multiple paths to stabilize revenues over months.
Gross Profit Positive Again After 2024 LossReturn to positive gross profit indicates product mix, pricing or cost-of-goods improvements at the core operating level. If sustained, positive gross margins enable operating leverage as volumes recover and are a prerequisite for restoring operating profitability over the medium term.
Sizable Asset Base Relative To Absolute DebtA meaningful asset base provides options: asset monetization, collateral for financing, or restructuring levers. With absolute debt modest versus assets, management has structural flexibility to pursue liquidity solutions or sales of noncore assets to shore up operations over several months.
Bears Say
Multi-year Revenue CollapseA dramatic and sustained loss of revenue destroys scale economics, weakens distributor and payor relationships, and reduces ability to cover fixed costs. Restoring previous scale will take substantial time or new product/adoption, making near-term recovery uncertain and structural.
Severely Negative Operating And Net MarginsExtremely wide negative margins reflect a cost base far exceeding current revenue and signal inefficient operations. Such deep losses erode capital, limit reinvestment, and normally require durable structural fixes—cost cuts, revenue restoration, or financing—to avoid ongoing deterioration.
Negative Equity And Persistent Cash BurnNegative equity alongside recurring negative operating cash flow indicates capital erosion and reliance on external funding or asset sales. This constrains financial flexibility, raises creditor risk, and creates structural solvency pressure unless cash generation meaningfully improves.
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $0.07 and its highest was $6.66 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $722.44K.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Aug 06, 2026 which is in 24 days.
How were Prophase Labs’s earnings last quarter?
Currently, no data Available
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 9,493,287 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prophase Labs
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Technical Analysis
Ownership Overview
37.75%
Insiders
0.23% Mutual Funds
0.89% Other Institutional Investors
61.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---